People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.0M | $4.0B | 2021 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2016 |
Peter Maag at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Maag on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 2 | 12 |
| Brook Byers | 1 | 13 |
| Michael Goldberg | 1 | 11 |
| Vijay Lathi | 1 | 8 |
| G. Steven Burrill | 1 | 7 |
| Ian Clark | 1 | 5 |
| Ryan Jones | 1 | 5 |
| William Hagstrom | 1 | 4 |
| Ralph Snyderman | 1 | 4 |
| David Levison | 1 | 3 |
| Peter Altman | 1 | 3 |
| Charles Constanti | 1 | 3 |
| Steve Liapis | 1 | 3 |
| Jean Frederic Viret | 1 | 2 |
| George Bickerstaff | 1 | 2 |
| Matthew Myer | 1 | 2 |
| Karen Walker | 1 | 2 |
| Brian Kotzin | 1 | 2 |
| James Chung | 1 | 2 |
| Anders Karlsson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.